Lutetium-177 - radiolabeled peptide therapy (Octreotate)

Lutetium-177 octreotate radioligand therapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium-177 - radiolabeled peptide therapy (Octreotate), covering 2022-07-05 to 2022-07-05. Get the full timeline:

Most recent: Clinical Trial Update: Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study [Phase 2]

See pricing